SCHEMBL2400677

SCHEMBL2400677

CN(C(=O)C(CC(=O)O)CC1CCCC1)c1nc(-c2cc(Cl)ccc2-c2cnc3c(c2)CC(=O)N3C)c(F)s1

nearest known ligand 0.44

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
FFAR2 O15552 8/20 0.44
CNR1 P21554 3/20 0.35
CXCR3 P49682 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2400672 1.00 FFAR2 (0.44) FFAR2CNR1CXCR3
SCHEMBL2398789 0.95 FFAR2 (0.42) FFAR2
SCHEMBL2398794 0.95 FFAR2 (0.42) FFAR2
SCHEMBL1917043 0.94 FFAR2 (0.46) FFAR2CNR1
SCHEMBL1917045 0.94 FFAR2 (0.46) FFAR2CNR1
SCHEMBL2399208 0.94 FFAR2 (0.44) FFAR2CNR1CXCR3
SCHEMBL2399214 0.94 FFAR2 (0.44) FFAR2CNR1CXCR3
SCHEMBL2398586 0.93 FFAR2 (0.48) FFAR2
SCHEMBL2398591 0.93 FFAR2 (0.48) FFAR2
SCHEMBL2397936 0.92 FFAR2 (0.44) FFAR2CNR1CXCR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110230477-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS EUROSCREEN S.A. (BE) 2011-09-22 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230477-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS CPT1A, LIPC, PC FFAR2 295/4885CNR1 841/4885CXCR3 2706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.